NCT Number: NCT07501494
The aim of the study is to identify and evaluate incentive mechanisms for the implementation of quality-relevant care processes. The objective is to correlate adherence to individual process-based quality indicators or their combination with outcome data. In addition, cost shares and case revenues are evaluated. Indices are also derived from routine data that may represent additional influencing factors (Charlson Comorbidity Index or secondary diagnoses that increase case severity based on ICD-10 coding and procedures based on the Surgery and procedure codes system).
Interested in participating?
Request Info18 year and older
All sexes
Observational
Berlin, 10117, Germany
Location status: Recruiting
Claudia Spies, MD, Prof.
CONTACT
Claudia Spies, MD, Prof.
PRINCIPAL_INVESTIGATOR
Oliver Kumpf, MD
SUB_INVESTIGATOR
Within the Department of Anesthesiology and Intensive Care Medicine CCM/CVK at Charité- University Medicine Berlin, the systematic evaluation of quality-related process indicators is standard practice. These are based on the intensive care quality indicators of the German Interdisciplinary Association for Intensive Care and Emergency Medicine (DIVI). These process-based indicators are to be correlated with the examination of outcome indicators from routine data transmission in accordance with §21 data record (e.g., 30-day readmission rate, mortality, infection rate, length of stay) and economic parameters of treatment from controlling data (Diagnosis Related Groups revenue, case costs). The §21 data record describes a standardized data format that hospitals are required to transmit to the Institute for the Hospital Remuneration System (InEK) in accordance with § 21 (4) and (5) Act on Fees for Full and Partial Inpatient Hospital Services (Hospital Fees Act - KHEntgG). Data on standard clinical care from the Charité hospital systems will be used.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-none
Time frame: 2012-2023
Per Case Revenue in Euro [€] (Revenue = base rate x DRG-rate) according to the Diagnosis Related Groups (DRG) reimbursement flat rate catalogue and the base rate for the state of Berlin for the respective billing year.
Time frame: 2012-2023
Per case costs in Euro [€] according to case-related analysis based on financial controlling data.
Time frame: 2012-2023
Charlson Comorbidity Indices are generated from the number and type of secondary diagnoses according to ICD-10 Diagnosis Related Groups coding.(Scale from 0-37; higher Score values indicating more severe comorbidities and less probability of 10-year survival)
Time frame: 2012-2023
30-day readmission rate from routine data up to one year
Time frame: 2012-2023
In-house mortality from routine data up to one year
Time frame: 2012-2023
Infection rate form routine data, based on ICD-10 coding
Time frame: 2012-2023
Length of hospital stay from routine data
Time frame: 2012-2023
Length of intensive care unit stay from routine data
Time frame: 2012-2023
Patient Related Outcome Measures (PROM) are collected from routine data of patients with Post Intensive Care Syndrome. Presence of PICS is based on ICD-10 codes and specific combinations.
Time frame: 2012-2023
Measures of circadian rhythms are determined using biometric routine data.
Time frame: 2012-2023
Degrees of fulfillment of process-based quality indicators based on Quality indicators the German Interdisciplinary Association for Intensive Care and Emergency Medicine (DIVI) are measured in percentages.
Time frame: 2012-2023
German Interdisciplinary Association for Intensive Care and Emergency Medicine (DIVI)-Quality indicator compliance is measured in dependence on primary and secondary diagnoses. The indicators are evaluated according to the following list:
QI1: "Ward round" QI2: "PAD-Management" QI3: "Mechanical ventilation" QI4: "Weaning from ventilation" QI5: "infection prevention" QI6: "management of infections" QI7: "nutrition management" QI8: "communication with relatives" QI9: "mobilization"
Time frame: 2012-2023
Degree of fulfillment of individual other process indicators based on German Interdisciplinary Association for Intensive Care and Emergency Medicine (DIVI) Quality indicators. In-House Quality measures like length of hospital stay or infection rates following surgery and their dependence on the fulfillment of DIVI-quality indicators. The indicators are evaluated according to the following list:
QI1: "Ward round" QI2: "PAD-Management" QI3: "Mechanical ventilation" QI4: "Weaning from ventilation" QI5: "infection prevention" QI6: "management of infections" QI7: "nutrition management" QI8: "communication with relatives" QI9: "mobilization"
Time frame: 2012-2023
Degree of fulfillment of individual other process indicators based on a combination of German Interdisciplinary Association for Intensive Care and Emergency Medicine (DIVI) Quality indicators (known as a "bundle"). The indicators are evaluated according to the following list:
QI1: "Ward round" QI2: "PAD-Management" QI3: "Mechanical ventilation" QI4: "Weaning from ventilation" QI5: "infection prevention" QI6: "management of infections" QI7: "nutrition management" QI8: "communication with relatives" QI9: "mobilization"
Contact information is provided by the study sponsor or research team.
Charite University, Berlin, Germany
Other
Retrospective Observational Study - Evaluation of Quality Indicators in Patients Receiving Intensive Care and Their Influence on Outcome Indicators and Economic Indicators
Acronym: EQUINOK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07567573
Adnexal Diseases, Advanced-stage Ovarian Cancer
Brussels, Belgium
View Trial DetailsNCT02030210
Cardiovascular Diseases, Heart Diseases
Leuven, Vlaams Brabant, Belgium
View Trial DetailsNCT01703689
Physical Disability, Quality Indicators
Albi, France
View Trial Details